Stock LFST LIFESTANCE HEALTH GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
6.86 USD -3.65% Intraday chart for LifeStance Health Group, Inc. +3.00% -12.39%
May. 09 LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated MT
May. 09 LifeStance Health Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LifeStance Health : Q1 2024 Earnings Script
PU
Transcript : LifeStance Health Group, Inc., Q1 2024 Earnings Call, May 09, 2024
LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated
MT
LifeStance Health Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
LifeStance Health Group, Inc. Announces Resignation of Danish Qureshi as President and Chief Operating Officer, Effective June 30, 2024
CI
Earnings Flash (LFST) LIFESTANCE HEALTH Posts Q1 Revenue $300.4M, vs. Street Est of $299M
MT
LifeStance Health: Q1 Earnings Snapshot
AQ
LifeStance Reports First Quarter 2024 Results
GL
LifeStance Health Group, Inc. Provides Earnings Guidance for the Second Quarter of 2024; Reiterates Earnings Guidance for the Full Year of 2024
CI
LifeStance Destigmatizes Mental Health in Newest "Not One Face" Campaign Featuring Photography from Leica Ambassadors
PR
LifeStance to Host First Quarter 2024 Earnings Conference Call on May 9, 2024
GL
LifeStance Appoints Dr. Teresa DeLuca to Board of Directors
PR
LifeStance Health Appoints Teresa DeLuca to Its Board of Directors
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST
PR
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating
MT
Lifestance Health Group Insider Sold Shares Worth $923,391, According to a Recent SEC Filing
MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating
MT
Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST
PR
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating
MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LFST Stock
  4. News LifeStance Health Group, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW